The purpose of this study is to demonstrate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration (AMD).
Pigment epithelial detachments (PED) secondary to age-related macular degeneration (AMD) have been excluded from practically all study populations of ranibizumab studies so far. PED represents a special entity in AMD. As yet, no standard treatment has been established for this disease.The stimuli that induce PED are not very well known, but there is evidence suggesting that angiogenic factors such as vascular endothelial growth factor (VEGF) also play a role in the pathogenesis. Ranibizumab is an anti-VEGF antibody fragment that blocks VEGF activity in patients with neovascular AMD.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
40
0.5 mg in 0.05 ml, monthly, 12 months
University Hospital Muenchen
München, Germany
University Hospital Muenster
Münster, Germany
To investigate the efficacy of ranibizumab in patients with retinal pigment epithelial detachment secondary to age-related macular degeneration
Time frame: 12 months
Safety
Time frame: 12 months
Mean change in best corrected visual acuity
Time frame: 12 months
Change in retinal thickness and height of pigment epithelial detachment
Time frame: 12 months
Central visual field and stability of fixation
Time frame: 12 months
Fluorescein leakage and changes in autofluorescence
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.